The One Peptide the FDA Panel Rejected — and Why That Vote Is the Most Informative of All
At the FDA’s July 2026 compounding panel, six peptides passed and one failed: emideltide (DSIP). Why that single rejection is the most revealing vote of all.
-
-
Samsung Biologics’ $1.8 Billion Bid for PolyPeptide: Why the Money Is Moving Into Peptide Manufacturing Capacity
Samsung Biologics has bid CHF 1.46bn for Swiss peptide CDMO PolyPeptide. A sober look at what the deal says about manufacturing capacity, and what it doesn’t.
-
Retatrutide Cleared Two More Phase 3 Trials — and Missed the Thing That Mattered Most
Lilly’s retatrutide passed TRIUMPH-2 and TRIUMPH-3 in July 2026 — but missed on cardiovascular events, and the FDA filing slipped to Q1 2027. An honest read.
-
The FDA Did Not Approve Six Peptides: What the July 2026 Compounding Vote Actually Was
An FDA panel recommended six of seven peptides for the 503A compounding list on 23-24 July 2026. That is not approval. What the vote did and did not do.
-
Which Peptides Has Andrew Huberman Said He Uses?
Which peptides Andrew Huberman has said he personally uses — pinealon, BPC-157, sermorelin — and what the primary literature actually shows about each.
-
Every Peptide Bryan Johnson Has Tried — and Why He Dropped Most of Them
Bryan Johnson has trialed CJC-1295, HGH, tirzepatide, cerebrolysin, epithalon, follistatin and BPC-157. A sourced look at what he measured, kept, and dropped.
-
Joe Rogan’s Peptide Use, Fact-Checked
Joe Rogan says he uses BPC-157 and TB-500 to heal injuries. We fact-check the claims against the actual literature — what holds up, what doesn’t.
-
Peter Attia on Peptides and Longevity Drugs, Fact-Checked
A source-checked look at where Peter Attia actually stands on NMN, rapamycin, metformin, GLP-1 drugs and BPC-157 — and where popular hype runs past the evidence.
-
Gary Brecka’s Peptide and Longevity Claims, Fact-Checked
A source-checked look at Gary Brecka’s claims on methylene blue, BPC-157, NAD+ and hydrogen — what the literature actually shows, and where certainty outruns data.
-
Bryan Johnson’s Peptide Stack, Fact-Checked: What the Evidence Actually Says
Blueprint’s founder has run dozens of peptides through his body and his biomarkers. Ranked by evidence, his protocol separates the plausible from the speculative — and his most instructive move was quitting something that “felt” like it worked.
